Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 20, Number 5—May 2014

Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 2

Socioeconomic characteristics of study participants and all patients with MDR and/or XDR TB, United States, 2005–2007*

Characteristic Study participants, no. (%), n = 135 All US MDR TB patients, no. (%), n = 370
Unemployed† 38 (28) 187 (51)
Homeless 9 (7) 20 (5)
Correctional institution resident 6 (4) 7 (2)
Long-term care facility resident
4 (3)
6 (2)
Injection drug use 5 (4) 8 (2)
Noninjection drug use† 12 (9) 15 (4)
Excess alcohol use 15 (11) 31 (8)
Smoker
31 (23)

Pregnant at treatment initiation 6 (4)
Private health insurance, % of 112 known 24 (21)
Public health insurance, % of 112 known 49 (44)
Jail/prison health coverage, % of 112 known 2 (2)
Other health insurance, % of 112 known 5 (4)
No health insurance, % of 112 known
32 (29)

HIV+ 14 (10) 29 (8)
Receiving HAART 9 (64)
Receiving ART 1 (7)
Receiving neither HAART nor ART 3 (21)
Receipt of ART not documented
1 (7)

Not HIV infected 102 (76) 205 (55)
HIV status unknown
19 (14)
136 (37)
Diabetes, % of 121 known 24 (20)
ESRD, % of 121 known 3 (2)
Prolonged corticosteroid therapy, % of 121 known 2 (2)
Other immunosuppressive therapy, % of 121 known 2 (2)
Cancer, % of 121 known 3 (2)
Hematologic diseases, % of 121 known 2 (2)

*Study patients were from California, New York City, and Texas. MDR, multidrug resistant; XDR, extensively drug resistant; TB, tuberculosis; HIV+, HIV infected; HAART, highly active antiretroviral therapy; ART, antiretroviral therapy; ESRD, end-stage renal disease. Blank cells indicate data not available.
†Statistically significant differences between percentages of study patients and all US MDR TB patients at p<0.05.

Main Article

TOP